These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 21899292)

  • 1. Discovery of (+)-N-(3-aminopropyl)-N-[1-(5-benzyl-3-methyl-4-oxo-[1,2]thiazolo[5,4-d]pyrimidin-6-yl)-2-methylpropyl]-4-methylbenzamide (AZD4877), a kinesin spindle protein inhibitor and potential anticancer agent.
    Theoclitou ME; Aquila B; Block MH; Brassil PJ; Castriotta L; Code E; Collins MP; Davies AM; Deegan T; Ezhuthachan J; Filla S; Freed E; Hu H; Huszar D; Jayaraman M; Lawson D; Lewis PM; Nadella MV; Oza V; Padmanilayam M; Pontz T; Ronco L; Russell D; Whitston D; Zheng X
    J Med Chem; 2011 Oct; 54(19):6734-50. PubMed ID: 21899292
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery and optimization of pyrimidone indoline amide PI3Kβ inhibitors for the treatment of phosphatase and tensin homologue (PTEN)-deficient cancers.
    Certal V; Carry JC; Halley F; Virone-Oddos A; Thompson F; Filoche-Rommé B; El-Ahmad Y; Karlsson A; Charrier V; Delorme C; Rak A; Abecassis PY; Amara C; Vincent L; Bonnevaux H; Nicolas JP; Mathieu M; Bertrand T; Marquette JP; Michot N; Benard T; Perrin MA; Lemaitre O; Guerif S; Perron S; Monget S; Gruss-Leleu F; Doerflinger G; Guizani H; Brollo M; Delbarre L; Bertin L; Richepin P; Loyau V; Garcia-Echeverria C; Lengauer C; Schio L
    J Med Chem; 2014 Feb; 57(3):903-20. PubMed ID: 24387221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel ATP-competitive kinesin spindle protein inhibitors.
    Parrish CA; Adams ND; Auger KR; Burgess JL; Carson JD; Chaudhari AM; Copeland RA; Diamond MA; Donatelli CA; Duffy KJ; Faucette LF; Finer JT; Huffman WF; Hugger ED; Jackson JR; Knight SD; Luo L; Moore ML; Newlander KA; Ridgers LH; Sakowicz R; Shaw AN; Sung CM; Sutton D; Wood KW; Zhang SY; Zimmerman MN; Dhanak D
    J Med Chem; 2007 Oct; 50(20):4939-52. PubMed ID: 17725339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization.
    Pevarello P; Brasca MG; Orsini P; Traquandi G; Longo A; Nesi M; Orzi F; Piutti C; Sansonna P; Varasi M; Cameron A; Vulpetti A; Roletto F; Alzani R; Ciomei M; Albanese C; Pastori W; Marsiglio A; Pesenti E; Fiorentini F; Bischoff JR; Mercurio C
    J Med Chem; 2005 Apr; 48(8):2944-56. PubMed ID: 15828833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study to assess the efficacy, safety and tolerability of the mitotic spindle kinesin inhibitor AZD4877 in patients with recurrent advanced urothelial cancer.
    Jones R; Vuky J; Elliott T; Mead G; Arranz JA; Chester J; Chowdhury S; Dudek AZ; Müller-Mattheis V; Grimm MO; Gschwend JE; Wülfing C; Albers P; Li J; Osmukhina A; Skolnik J; Hudes G
    Invest New Drugs; 2013 Aug; 31(4):1001-7. PubMed ID: 23329066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metal-Dependent Cytotoxic and Kinesin Spindle Protein Inhibitory Activity of Ru, Os, Rh, and Ir Half-Sandwich Complexes of Ispinesib-Derived Ligands.
    Łomzik M; Hanif M; Budniok A; Błauż A; Makal A; Tchoń DM; Leśniewska B; Tong KKH; Movassaghi S; Söhnel T; Jamieson SMF; Zafar A; Reynisson J; Rychlik B; Hartinger CG; Plażuk D
    Inorg Chem; 2020 Oct; 59(20):14879-14890. PubMed ID: 33003697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis and evaluation of biphenyl compounds as kinesin spindle protein inhibitors.
    Holland JP; Kang A; Cohrs S; Selivanova SV; Milicevic Sephton S; Betzel T; Frey D; Wieser M; Jaussi R; Kammerer RA; Schibli R; Fischer E
    Chem Biodivers; 2013 Apr; 10(4):538-55. PubMed ID: 23576341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinesin spindle protein (KSP) inhibitors. Part 6: Design and synthesis of 3,5-diaryl-4,5-dihydropyrazole amides as potent inhibitors of the mitotic kinesin KSP.
    Coleman PJ; Schreier JD; Cox CD; Fraley ME; Garbaccio RM; Buser CA; Walsh ES; Hamilton K; Lobell RB; Rickert K; Tao W; Diehl RE; South VJ; Davide JP; Kohl NE; Yan Y; Kuo L; Prueksaritanont T; Li C; Mahan EA; Fernandez-Metzler C; Salata JJ; Hartman GD
    Bioorg Med Chem Lett; 2007 Oct; 17(19):5390-5. PubMed ID: 17761419
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
    Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
    Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triphenylbutanamines: kinesin spindle protein inhibitors with in vivo antitumor activity.
    Wang F; Good JA; Rath O; Kaan HY; Sutcliffe OB; Mackay SP; Kozielski F
    J Med Chem; 2012 Feb; 55(4):1511-25. PubMed ID: 22248262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity.
    Klutchko SR; Hamby JM; Boschelli DH; Wu Z; Kraker AJ; Amar AM; Hartl BG; Shen C; Klohs WD; Steinkampf RW; Driscoll DL; Nelson JM; Elliott WL; Roberts BJ; Stoner CL; Vincent PW; Dykes DJ; Panek RL; Lu GH; Major TC; Dahring TK; Hallak H; Bradford LA; Showalter HD; Doherty AM
    J Med Chem; 1998 Aug; 41(17):3276-92. PubMed ID: 9703473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Receptor-ligand interaction-based virtual screening for novel Eg5/kinesin spindle protein inhibitors.
    Nagarajan S; Skoufias DA; Kozielski F; Pae AN
    J Med Chem; 2012 Mar; 55(6):2561-73. PubMed ID: 22309208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase I study to assess the safety, tolerability, and pharmacokinetics of AZD4877, an intravenous Eg5 inhibitor in patients with advanced solid tumors.
    Infante JR; Kurzrock R; Spratlin J; Burris HA; Eckhardt SG; Li J; Wu K; Skolnik JM; Hylander-Gans L; Osmukhina A; Huszar D; Herbst RS
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):165-72. PubMed ID: 21638123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors.
    Jiang C; Yang L; Wu WT; Guo QL; You QD
    Bioorg Med Chem; 2011 Sep; 19(18):5612-27. PubMed ID: 21856161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One pot synthesis of thiazolodihydropyrimidinones and evaluation of their anticancer activity.
    Holla BS; Rao BS; Sarojini BK; Akberali PM
    Eur J Med Chem; 2004 Sep; 39(9):777-83. PubMed ID: 15337290
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and antitumor activity of novel pyrido[2,3-d][1,2,4]triazolo[4,3-a]pyrimidin-5-one derivatives.
    El-Nassan HB
    Eur J Med Chem; 2011 Jun; 46(6):2031-6. PubMed ID: 21429629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of (2E)-3-{2-butyl-1-[2-(diethylamino)ethyl]-1H-benzimidazol-5-yl}-N-hydroxyacrylamide (SB939), an orally active histone deacetylase inhibitor with a superior preclinical profile.
    Wang H; Yu N; Chen D; Lee KC; Lye PL; Chang JW; Deng W; Ng MC; Lu T; Khoo ML; Poulsen A; Sangthongpitag K; Wu X; Hu C; Goh KC; Wang X; Fang L; Goh KL; Khng HH; Goh SK; Yeo P; Liu X; Bonday Z; Wood JM; Dymock BW; Kantharaj E; Sun ET
    J Med Chem; 2011 Jul; 54(13):4694-720. PubMed ID: 21634430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pyrimidinedione-mediated selective histone deacetylase 6 inhibitors with antitumor activity in colorectal cancer HCT116 cells.
    Liu YM; Lee HY; Lai MJ; Pan SL; Huang HL; Kuo FC; Chen MC; Liou JP
    Org Biomol Chem; 2015 Oct; 13(40):10226-35. PubMed ID: 26309122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorinated quinazolinones as potential radiotracers for imaging kinesin spindle protein expression.
    Holland JP; Jones MW; Cohrs S; Schibli R; Fischer E
    Bioorg Med Chem; 2013 Jan; 21(2):496-507. PubMed ID: 23245569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and discovery of 6-[(3S,4S)-4-methyl-1-(pyrimidin-2-ylmethyl)pyrrolidin-3-yl]-1-(tetrahydro-2H-pyran-4-yl)-1,5-dihydro-4H-pyrazolo[3,4-d]pyrimidin-4-one (PF-04447943), a selective brain penetrant PDE9A inhibitor for the treatment of cognitive disorders.
    Verhoest PR; Fonseca KR; Hou X; Proulx-Lafrance C; Corman M; Helal CJ; Claffey MM; Tuttle JB; Coffman KJ; Liu S; Nelson F; Kleiman RJ; Menniti FS; Schmidt CJ; Vanase-Frawley M; Liras S
    J Med Chem; 2012 Nov; 55(21):9045-54. PubMed ID: 22780914
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.